Guidelines on Bladder Cancer

Oosterlinck, Willem; Lobel, Bernard; Jakse, G.; Malmström, Per Uno; Stöckle, Michael; Sternberg, Cora N.

doi:10.1016/s0302-2838(01)00026-4

Cited by 386 publications

(196 citation statements)

References 57 publications

Supporting

Mentioning

174

Contrasting

Unclassified

Order By: Relevance

“…35 The European Association of Urology (EAU) guidelines echo this viewpoint by mentioning cystectomy as the treatment of choice for CIS patients failing adequate BCG and as an option in other high-risk tumors. 150 Recurrent aggressive disease 6 months after diagnosis or disease persisting after 2 courses of BCG therapy is a strong indication to consider radical therapy. 139 When patients with nonmuscle-invasive bladder cancer have a recurrence with invasive disease, a window of opportunity is missed, which emphasizes the importance of close, active surveillance and aggressive treatment of patients with high-risk nonmuscle-invasive disease.…”

Section: Nonmuscle-invasive Diseasementioning

confidence: 99%

Bladder Cancer in 2010: How Far have We Come?

Jacobs¹,

Lee

Montie

2010

CA: A Cancer Journal for Clinicians

298

275

View full text Add to dashboard Cite

Bladder cancer is the fourth most common cancer and ranks eighth as a cause of death from cancer among men in the United States. Although guidelines assist in treatment, the art of managing bladder cancer, such as the decision to use neoadjuvant chemotherapy and the timing of cystectomy, is still variable. Bladder cancer has a propensity to recur, and with recurrence, a significant number of cases progress, which makes the early detection of high-risk patients imperative. Advances in detection, surveillance, and treatment of bladder cancer are reviewed in this article.

show abstract

Section: Nonmuscle-invasive Diseasementioning

confidence: 99%

Bladder Cancer in 2010: How Far have We Come?

Jacobs¹,

Lee

Montie

2010

CA: A Cancer Journal for Clinicians

298

275

View full text Add to dashboard Cite

show abstract

“…Patients who had undergone RC had initially been treated with TURBT that had shown ≥pT2 bladder cancer. Six out of 14 patients with superficial UC were classified as low-risk, 5 as intermediate risk and 3 as high-risk, according to the European Association of Urology (EAU) Working Group on Oncological Urology classification (17). Among those patients undergoing TURBT, 7 received adjuvant treatment for 6 weeks with weekly Bacillus Calmette-Guérin (BCG) instillations at an average interval of 21 days after the operation.…”

Section: Study Populationmentioning

confidence: 99%

E-cadherin mRNA expression analysis in evaluating the natural history of urothelial bladder cell carcinoma: Results from a long-term follow-up study

Cai

Piazzini²,

Nesi³

et al. 2007

Oncol Rep

View full text Add to dashboard Cite

Abstract. Many studies have indicated that the E-cadherin (E-CAD) expression loss is associated with the loss of cellular differentiation and increased cellular invasiveness and can be correlated with poor prognosis in urothelial carcinoma (UC) of the urinary bladder. The aim of this study was to define the role of E-CAD mRNA expression on recurrence, progression and survival in UC of the urinary bladder over a long follow-up period. From 30 patients with bladder UC, enrolled in our previous study, 27 were selected for this study. All patients were re-analyzed in terms of clinical and tumor characteristics, tumor pathological analysis and tumor E-CAD mRNA expression. The data were correlated to 12-year follow-up results. Significant correlations between stage (p=0.002), grade (p=0.008) and E-CAD mRNA expression were reported. E-CAD did not show any correlation in predicting recurrence or progression in bladder UC. The survival analysis demonstrated a significant relationship (p=0.019) between patients with expressed E-CAD mRNA levels and cancer-specific survival. Multivariate analysis demonstrated that expression of E-CAD mRNA levels is an independent prognostic factor in terms of cancerspecific survival in UC of the urinary bladder (p=0.002). Our study is the first to demonstrate that mRNA extraction and Northen blot analysis is to be considered a reliable method to evaluate E-CAD mRNA levels for predicting survival rate in patients affected by urothelial bladder cancers. We stress that a long follow-up period is needed to evaluate the role of molecular factors in predicting prognosis in patients affected by bladder UC.

show abstract

“…Urothelial carcinoma of the bladder is usually multifocal, frequently shows clinical relapses along the genitourinary tract [3] and it is characterized by immunohistochemical positivity for CK20, CK7, p63 and p53. [4][5] The main primary sites for metastatic bladder carcinoma are liver, lung and bone.…”

Section: Discussionmentioning

confidence: 99%